World News: 14:00 GMT Tuesday 3rd December 2019. [Rafael Pharmaceuticals, Inc. via Globe Newswire via SPi World News]
Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Co-Chief Medical Officer, Timothy Pardee, M.D., Ph.D., will lead a on the Phase 3 study of for the treatment of older patients with relapsed or refractory acute myeloid leukemia (AML) at the .
Dr. Pardee will present the study design and method of testing the efficacy of devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone alone for older patients (≥60 years of age) with relapsed or refractory AML in . He will speak to the natural history of AML in older adults, along with highlighting the positive results that prior studies testing devimistat for patients with relapsed/refractory AML have identified.
“Dr. Pardee continues to be instrumental in the development of devimistat, and we are honored that he was selected to share his research and expertise at ASH,” said Sanjeev Luther, CEO and President of Rafael. “Devimistat may fill a significant gap in treating relapsed or refractory AML, as Dr. Pardee’s research demonstrates.”
The Annual ASH Meeting and Exposition will be held in Orlando, Florida from Dec. 7 through 10. ASH has more than 17,000 members from more than 100 countries and is the largest society serving both clinicians and scientists around the world who are working to conquer blood diseases.
Globe Newswire: 14:00 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.